[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:oropharyngeal-carcinoma:cdkn2a-wt-allele":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Oropharyngeal Carcinoma","CDKN2A wt Allele",16,[8,16,22,28,34,40,46,52,58,64,70,76,82,89,95,101],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07178301","Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:15:58.452248Z","2026-07-19T19:36:05.065224Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06984861","A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:29.643338Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06554158","De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers",[],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.477332Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT03215719","Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.074089Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.218746Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT05799144","pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w\u002FAdvanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.217841Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT05388773","Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer",[12],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.421473Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.405933Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":62,"content_modified":63},"NCT06309225","Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly",[],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.403976Z",{"nct_id":65,"title":66,"phases":67,"status":13,"updated_at":68,"content_modified":69},"NCT05800574","Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.274627Z",{"nct_id":71,"title":72,"phases":73,"status":13,"updated_at":74,"content_modified":75},"NCT07290621","Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:26.936724Z",{"nct_id":77,"title":78,"phases":79,"status":13,"updated_at":80,"content_modified":81},"NCT06445114","Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:27.435233Z","2026-04-29T02:57:57.120187Z",{"nct_id":83,"title":84,"phases":85,"status":13,"updated_at":87,"content_modified":88},"NCT05172245","Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer",[86],"Phase 1","2026-08-26T02:17:41.695983Z","2026-07-19T19:36:05.120891Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT07195734","Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer",[12],"2026-08-26T02:18:11.042248Z","2026-07-05T05:32:16.659005Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT07156227","Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma",[86],"2026-08-26T02:17:44.240289Z","2026-06-04T01:30:07.902043Z",{"nct_id":102,"title":103,"phases":104,"status":105,"updated_at":106,"content_modified":107},"NCT04444869","Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer",[12],"UNKNOWN","2026-08-03T01:56:19.375288Z","2026-05-05T02:43:27.629541Z"]